Help
Subscribe


All of GastroHep is now free access! - Click here to register Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Increasing body mass index influences response to treatment with dexlansoprazole or lansoprazole

A study published ahead of print the Alimentary Pharmacology & Therapeutics examines the effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole.

News image

Higher body mass index is a recognised risk factor for gastro-esophageal reflux disease (GERD).

Data regarding the impact of body mass index on proton pump inhibitor therapy are conflicting.

Dr Peura and colleagues assessed the impact of body mass index on baseline heartburn symptom severity and frequency and response to proton pump inhibitor therapy in patients with non-erosive gastro-esophageal reflux disease or erosive esophagitis.

In post hoc analyses of phase 3 trial data, 621 gastro-esophageal reflux disease and 2692 erosive esophagitis patients were stratified by body mass index.

The researchers noted that gastro-esophageal reflux disease patients received either dexlansoprazole MR 30 mg or placebo daily for 4 weeks.

Erosive esophagitis patients received either dexlansoprazole MR 60 mg or lansoprazole 30 mg for 8 weeks.

The team of doctors assessed the symptom frequency and severity at baseline and subsequently by daily diary.

PPI reduction in symptoms were similar across body mass index categories
Alimentary Pharmacology & Therapeutics

In both the gastro-esophageal reflux disease and erosive esophagitis cohorts, baseline heartburn severity increased with increasing body mass index.

The impact of proton pump inhibitor therapy on the reduction in heartburn symptom frequency and severity in both gastro-esophageal reflux disease and erosive esophagitis patients was similar across body mass index categories.

The researchers found that erosive esophagitis healing rates in patients treated with dexlansoprazole but not lansoprazole were higher in obese patients compared with those with a body mass index 30 kg/m2.

Differences between the proton pump inhibitor were small.

Dr Peura's team concluded, "The proton pump inhibitor evaluated in this study reduced the frequency and severity of 24-hour heartburn regardless of baseline body mass index."

"In addition, because patients with higher body mass index have more severe symptoms at baseline, they may experience greater therapeutic gain with dexlansoprazole and possibly lansoprazole treatment."

Aliment Pharmacol Ther 2013: DOI: 10.1111/apt.12270
13 March 2013

Go to top of page Email this page Email this page to a colleague

 02 July 2015

Advanced search
 02 July 2015 
Anastomotic leak and cancer cancer
 02 July 2015 
Ulcerative colitis prognosis after thiopurines withdrawal
 02 July 2015 
Health care use by IBD children
 01 July 2015 
Missed gastric cancers
 01 July 2015 
Probiotics in IBD
 01 July 2015 
Oral mechanical bowel preparation
 30 June 2015 
Glucocorticoids and peptic ulcer bleeding
 30 June 2015 
Split-dose preparations vs day-before bowel cleansing regimens
 30 June 2015 
NSAIDs and hearburn symptoms
 29 June 2015 
Rescue therapy in ulcerative colitis
 29 June 2015 
Prevention of pancreatitis after ERCP
 29 June 2015 
Advances in autoimmune pancreatitis
 26 June 2015 
Dietary fibre–microbiota interactions
 26 June 2015 
Gastritis in celiac disease
 26 June 2015 

Gene polymorphism in alcoholic liver disease

 25 June 2015 
Fecal microbiota in pediatric IBD
 25 June 2015 
Vitamin D level and primary biliary cirrhosis
 25 June 2015 
Persistent organ failure in acute cholangitis patients
 24 June 2015 
Fatigue scales for IBD
 24 June 2015 
Mucosal healing tests in ulcerative colitis
 24 June 2015 
Environmental risk in IBD
 23 June 2015 
Marker associated with endoscopic lesion in Crohn's
 23 June 2015 
Body composition in children with IBD
 23 June 2015 
Medical vs nurse endoscopists
 22 June 2015 
Gene polymorphism associated with increased liver enzymes
 22 June 2015 
Treatment of uncomplicated acute appendicitis
 22 June 2015 
Solid organ cancers after liver transplant
 19 June 2015 
Causes of death in HBV
 19 June 2015 
Lifetime benefits of increased adenoma detection rates
 19 June 2015 
Acid-suppressive therapy before anti-reflux surgery
 18 June 2015 
Endoscopic activity in symptomatic IBD patients
 18 June 2015 
Regimens for H. pylori eradication
 18 June 2015 
Risk for dyspepsia
 17 June 2015 
NAFLD risk in celiac disease
 17 June 2015 
Non-invasive markers of advanced liver fibrosis
 17 June 2015 
Patients’ and clinicians’ perception of pouch dysfunction
 16 June 2015 
Risk score for hepatocellular carcinoma screening
 16 June 2015 
Esophageal food bolus impaction
 16 June 2015 
Evaluating lymph node metastasis for rectal cancer
 15 June 2015 
Low-cost colonoscopy training
 15 June 2015 
Determining dysbiosis in IBS or IBD
 15 June 2015 
Light alcohol consumption and NAFLD
 12 June 2015 
Smoking and disease course in IBD
 12 June 2015 
Hep D in a Hep B endemic area
 12 June 2015 
Patient-orientated internet information in ulcerative colitis
 11 June 2015 
Physical inactivity and NAFLD
 11 June 2015 
Esophageal stricture after endoscopic resection
 11 June 2015 
Guideline based screening strategies for hepatitis
 10 June 2015 
Cost-effectiveness of HCV treatment in liver disease
 10 June 2015 
Abdominoperineal excision for low rectal cancer
 10 June 2015 
Pediatric chronic Hep C
 09 June 2015 
Bile acid malabsorption in IBS
 09 June 2015 
Racial differences in celiac disease
 09 June 2015 
Conversion from laparoscopic to open colorectal cancer resection
 08 June 2015 
Short sleep duration and NAFLD
 08 June 2015 
Heritability in inflammatory bowel disease
 08 June 2015 
Eosinophilic esophagitis
 05 June 2015 
In-hospital mortality in patients with lower GI bleeding
 05 June 2015 
Scoring system for microscopic colitis
 05 June 2015 
H. pylori and myocardial infarction

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2015 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us